BioGeneration Ventures (BGV) is a venture capital firm specializing in seed investments in innovative early-stage European life sciences companies. BGV typically acts as the lead investor, focusing on biotech companies developing disruptive solutions for high unmet medical needs. BGV is the early-stage strategy of the Forbion-BGV platform of funds, which also includes Forbion Ventures and Forbion Growth. The firm supports biotech companies throughout all stages of development, from company formation (Build, Seed, Series A) through company building (Build, Enable, Series A-B) and company expansion (Crossovers, VIPE/PIPE, Series B/C). They look for opportunities to translate rough scientific ideas into therapeutic products, emphasizing patient impact and attracting additional investment.
Preferred startup development maturity for initial funding deployment.
Biotech, Life Sciences, Pharmaceuticals, Therapeutics, Oncology, Immunology, Nephrology, Chronic Diseases, Cell Therapy, Synthetic Lethality in Cancer
Core thematic spaces, technologies, and target market segments of interest.
Standard financial allocation per investment round.
Direct Verification Contact Email Pattern
Thesis Dossier Analysis Scorecard
Our agent analyzer scanned portfolio holdings and verified absolute match parameters...